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g.2014.0Abstract Background: Inherited thrombophilia may be caused by mutations, polymorphisms in a
variety of genes mainly involved in haemostatic pathways.
Aim of the study, was to ﬁnd the prevalence of thrombophilic gene factor V Leiden (FVL) and
methylene tetrahydrofolate reductase (MTHFR) gene polymorphism in patients with myocardial
infarction (MI), aiming at early diagnostic methods and guiding preventive procedures.
Subjects and methods: This study was carried on 30 patients who survived their ﬁrst MI as com-
pared to 15 healthy volunteers. Patients and controls were subjected to history, physical examina-
tion. Factor VL G1691A and MTHFR C677T genotypes were determined by RT PCR.
Results: The prevalence of heterozygous FVL GA genotype was signiﬁcantly higher among MI
patients as compared to the control group. The prevalence of mutant homozygous AA was signif-
icantly higher in MI patients as compared to control. The low risk cases had a higher frequency of
GA genotype as compared to high risk cases.
As regards MTHFR C677T gene polymorphism, the prevalence of heterozygous MTHFR C677T
CT genotype showed signiﬁcant increase in MI patients compared with the control group. The prev-
alence of mutant homozygous TT genotype was signiﬁcantly higher in MI patients as compared to
the control group. The low risk cases had a higher frequency of heterozygous MTHFR C677T CT
genotype than high risk cases.6236832.
m (H. Ezzat).
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114 H. Ezzat et al.To conclude: The prevalence of heterozygous (FVL G1691A) and MTHFR C677T gene poly-
morphisms was signiﬁcantly increased in MI patients compared with the control group and these
gene polymorphisms are probably risk factors for myocardial infarction among Egyptian cases
especially if integrated with other environmental and genetic risk factors. We recommended screen-
ing high risk patients for this polymorphism and the use of speciﬁc thromboprophylaxis to prevent
recurrent thrombotic disease.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Myocardial infarction (MI) is one of the leading causes of
death worldwide. MI has a high prevalence especially in the el-
derly [1]. However, the age of MI onset has decreased because
of environmental risk factors and genetic polymorphisms [2].
Myocardial infarction reﬂects cell death caused by myocar-
dial ischemia. Myocardial infarction may occur with typical
symptoms, or even without symptoms, being detected only by
ECG, cardiac biomarker elevations, or cardiac imaging [3].
Myocardial infarction is inﬂuenced by genetic and environmen-
tal factors. Family history of coronary artery disease, obesity,
inﬂammation, hypertension, dyslipidemia, diabetes, and smok-
ing, all are factors that constitute a major risk factor for MI [4].
Many susceptible gene candidates have been conﬁrmed to
be highly associated with the onset and prognosis of MI. Even
some well-known etiologic risk factors probably have genetic
backgrounds [5].
Thrombophilia refers to a series of acquired and inherited
conditions that confer a tendency to thrombus formation.
Inherited thrombophilia may be caused by mutations and
polymorphisms in a variety of genes mainly involved in hae-
mostatic pathways. These genes are included in coagulation,
ﬁbrinolysis, and platelet glycoprotein receptor function and
homocysteine metabolism. Thrombophilic genes are well rec-
ognized as common risk factors for venous thromboembolic
disorders. However, the relationship between inherited throm-
bophilias and arterial disease is still unresolved [6,7].
The exact relationship between thrombophilia andMI is not
well established. In the last years the attention has been focused
on polymorphisms inﬂuencing some biological functions [8].
Among the candidate markers for inherited cardiovascular
disease (CVD) risk, are variations in the genes for blood coagu-
lation factors V (FV) and methylene tetrahydrofolate reductase
(MTHFR) [9]. Thrombophilia may contribute to the develop-
ment of MI in a speciﬁc group of young patients [10].
FV Leiden mutation (FVL) is caused by single point muta-
tion of guanine to adenine transition at nucleotide 1691 in the
factor V gene. This mutation leads to a substitution of amino
acid arginine by glutamine at position 506. This results in fail-
ure of activated protein C (APC) to recognize a major cleavage
site on factor V, which led to increased thrombin generation
[11]. Carriers of FVL develop hypercoagulability. Most homo-
zygotes for FVL were reported to get at least one venous
thromboembolic (VTE) event in their life time [12].
Methylene tetrahydrofolate reductase (MTHFR) is a key en-
zyme in homocysteine (Hcy) metabolism. MTHFR is responsi-
ble for the circulating form of folate, 5-methyl-tetrahydrofolate,
which provides methyl groups for the remethylation of homo-
cysteine to methionine [13]. Hyperhomocysteinemia is the con-
sequence of decreased activity of MTHFR and is associatedwith a slight increase in the risk for thrombosis [14]. A common
mutation (C677T) has been identiﬁed in theMTHFRgene. It re-
sults from the alteration of alanine to valine amino acid. Com-
mon C677T polymorphism in MTHFR has been associated
with an increased risk for the development of cardiovascular dis-
ease, Alzheimer’s disease, depression in adults, and neural tube
defects in the fetus [15]. The population frequencies of homozy-
gous MTHFR C677T vary in the United States from 44.6% in
Caucasians, 42% in Hispanics and 25.6% African American
[16].
The present work was designed to study the prevalence of
the thrombophilic (Factor VL G1691A and MTHFR
C677T) gene polymorphisms in patients with myocardial
infarction, aiming at early diagnostic methods and guiding pre-
ventive procedures.
2. Subjects and methods
This cross sectional study was conducted at Internal Medicine
Department at Al-Zahraa University Hospital and Sayed Ga-
lal University Hospital, Cairo, Egypt.
The study was carried on two groups. The patient group
consisted of 30 patients who survived their ﬁrst acute myocar-
dial infarction based on clinical, electrocardiographic (ECG)
and laboratory data (24 males, 6 females, and mean age
45.5 ± 4.8 years).
A control group (n= 15) consisted of healthy volunteers,
(11 males, 4 females, mean age 43.2 ± 4.3 years), Control sub-
jects were free of clinical manifestations of coronary artery dis-
ease; none of them had history of venous thrombosis,
hypertension or diabetes.
Cases were further classiﬁed into high risk group with two
or more risk factors and low risk group with no or only one
risk factor.
Important risk factors are previous cardiovascular disease,
old age, tobacco smoking, high serum levels of low-density
lipoprotein (LDL) cholesterol, triglycerides and low levels of
high density lipoprotein (HDL) cholesterol, diabetes, high
blood pressure, lack of physical activity, obesity, chronic kid-
ney disease, and chronic high stress [17,18].
The exclusion criteria for all groups include: history of pre-
vious venous thrombosis, liver disease, or any collagen dis-
eases, presence of any form of cancer, diabetes, history of
acquired causes of thrombophilia, such as antiphospholipid
antibody syndrome, and recent surgery or trauma.
The work was done after taking acceptance of all patients
and controls to share in the study as well as acceptance of eth-
ics committee of the university.
The works have been carried out in accordance with the
code of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments involving humans.
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1- All participants gave a complete medical history that
included cardiovascular risk factors, such as obesity,
smoking habits, hypertension, diabetes, dyslipidemia,
and family history of MI. Subjects were deemed dyslip-
idemic when their total cholesterol concentration was
above 220 mg/dl or their triglyceride concentration was
above 200 mg/dl, or if they were receiving lipid-lowering
drugs.
Smoking history was coded by grouping patients into
non-smokers who had never smoked and those who
were or had been smokers. A family history of MI was
deﬁned based on its presence in ﬁrst-degree relatives.
2- Complete general examination including blood pressure
measurement and measurement of body mass index
(BMI), body mass index is deﬁned as the individual’s
body weight divided by the square of his or her height
in meter (kg/m2).
3- Electrocardiographic examination (ECG).
4- Routine laboratory investigations which include fasting
blood sugar, liver function and kidney function tests,
complete blood picture and lipid proﬁles.
5- Factor VL G1691A and MTHFR C677T genotypes
were determined by RT PCR.
2.1. Laboratory investigations
Venous blood samples were obtained in the morning after an
overnight fasting (10 h) from all patients and controls. Blood
samples were divided into two portions as follows:
- First portion, 2 ml was put in EDTA tube for genetic anal-
ysis by RT (PCR)
- Second portion, 5 ml was put in a plan tube, left to clot then
centrifuged at 1500 rpm for 10 min. Serum was separated
and used for estimation of biochemical variables.
This included: glucose, creatinine, cholesterol, triglycerides,
high density lipoprotein-cholesterol (HDL-c). These were mea-
sured using COBAS INTEGRA 400 plus, Autoanalyzer
using Kits supplied from Roche Diagnostics. Mannheim, Ger-
many (as routine follow up).
2.2. DNA extraction and molecular genetic screening
Genomic DNA was extracted from whole EDTA blood by
Roche Diagnostics high pure PCR template preparation Kit
(Cat.-No. 11 796 828 001). The following loci of genes encod-
ing for proteins involved in blood coagulation were analyzed:
(1) factor V Leiden mutation and (2) MTHFR C677T.
Eluted DNA was stored in screw cap tubes at 80 C and
thawed once at time of use.
2.3. Detection of factor V Leiden gene polymorphism
FVL G1691 A, Kit Cat No (03 610 179 001) supplied by Roche
Diagnostics GmbH, Mannheim, Germany, was used for detec-
tion of factor V Leidenmutation in the extractedDNA samples.
The Kit is tested on the Light Cycler 2 Instrument (RT, PCR).2.3.1. Detection
1. A 222 bp fragment of the factor V gene is ampliﬁed
from human genomic DNA using speciﬁc primers.
2. The resulting PCR fragments are analyzed with hybrid-
ization probes labeled with Light Cycler Red 640
(detected in channel 640n). The genotype is identiﬁed
by running a melting curve with speciﬁc melting points
(Tm) The wild type factor V DNA exhibits a Tm of
66.0 C in channel 640. The mutant Factor V exhibits
a Tm of 57 C in channel 640.
The specimen preparation was performed according to the
workﬂow procedures described in the package insert.
The reagent include, 2 ll of the light cycler factor V Leiden
mutation detection mix, 2 ll of the light cycler factor V reac-
tion mix and 11 ll of PCR grad water supplied with the kit.
Mix gently and transfer to a Light Cycler Capillary (Light Cy-
cler 2 Instrument). 5 ll of sample or control DNA was added
to each capillary or well for a ﬁnal reaction volume of 20 ll.
(Negative control: template DNA was replaced by Water) (Po-
sitive control: contains provided control DNA along with the
kit) then run was start.
2.3.2. Light cycler programming
The protocol consists of four programme steps:
Denaturation, one cycle 95 C for 10 min; Cycling, 45 cy-
cles of 95 C for 10 s, 58 C for 10 s and 72 C for 15 s; Melting
curve analysis, one cycle of 95 C for 20 s, 40 C for 20 s then
85 C for 0 s; followed by a single Cooling cycle 40 C for 30 s.
2.3.3. Specimen result
The assay result for the FV leiden data in channel 640 ‘‘Tm
Calling’’ Analysis mode (LightCycler 2 Instrument) should al-
ways exhibit a melting curve proﬁle for the homozygous wild-
type, homozygous mutant or heterozygous genotype. The neg-
ative control must show no signal (Fig. 1).
2.3.4. Interpretation of data
Homozygous G/G variant, the wild type factor V DNA exhib-
its a Tm of 66 C in channel 640
Heterozygous G/A variant exhibits two peaks one at 66 C
and another one at 57 C in channel 640
Homozygous A/A variant: The mutant factor V Leiden
exhibits a Tm of 57 C in channel 640.
2.4. Detection of MTHFR C677T gene polymorphism
The Light Mix Kit (MTHFR C677T) Cat No (40-0095-16)
supplied by Roche Diagnostics GmbH, Mannheim, Germany
was used for detection of MTHFR C677T polymorphic loci
in the extracted DNA samples. The Kit is tested on the Light
Cycler 2 (RT PCR).
2.4.1. Detection
1- A 233 bp fragment of the human MTHFR gene is
ampliﬁed with speciﬁc primers. The resulting PCR frag-
ments are analyzed with hybridization probes labeled
with Light Cycler Red 640 (detected in channel 640n).
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Figure 2 Light cycler 2 instrument Roch master, sample data for MTHFR C677T at channel 640.
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Figure 1 Light cycler 2 instrument Roch master, sample data for factor V leiden at channel 640.
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with speciﬁc melting points (Tm). The wild type
MTHFR C677 DNA exhibits a Tm of 63.0 C in chan-
nel 640. The mutant MTHFR 677 exhibits a Tm of
54.5 C in channel 640.2.4.2. Preparation of light cycler reaction mix
The reaction mix for each sample (single reaction mix) consists
of the following: 7.4 lL PCR grade water, (provided with the
Roche Master kit), 1.6 lL magnesium solution (Roche Fast-
Start kit) + 4 lL reagent mix (primers and probes) + 2 lL
Roch master (enzymes). Mix gently, and transfer 15 ll each
of the reaction mix to a LightCycler Capillary (LightCycler 2
Insturment). Add 5 ll of sample or control DNA to each cap-
illary or well for a ﬁnal reaction volume of 20 ll (Negative con-
trol: template DNA was replaced by Water) (Positive control:
contains provided control DNA).
2.4.3. Light cycler programming
The protocol consists of four programme steps:
Denaturation, one cycle 95 C for 10 min; Cycling, 45 cy-
cles of 95 C for 5 s, 60 C for 10 s and 72 C for 15 s; Melting
curve analysis, one cycle of 95 C for 20 s, 40 C for 20 s then
85 C for 0 s; followed by a single Cooling cycle 40 C for 30 s.
2.4.4. Data analysis
View MTHFR C677T data in channel 640 ‘‘Tm Calling’’ Anal-
ysis mode (LightCycler 2 Instrument). The negative control
must show no signal (Fig. 2).
2.4.5. Interpretation of data
Homozygous C/C variant, the wild type MTHFR C677 DNA
exhibits a Tm of 63 C in channel 640.Heterozygous C/T variant exhibits two peaks one at 54.5
and another one at 63 C in channel 640.
Homozygous T/T variant: The mutant MTHFR 677T
exhibits a Tm of 54.5 C in channel 640.
2.5. Statistical analysis
Data were analyzed using SPSS statistical package for Social
Sciences version 13 for Windows. Quantitative variables were
described using mean (±) standard deviation and categorical
data by using percentage. Comparison between groups was
done using Chi square (X2) test for qualitative variables, t-test
for normally distributed variables. P value <0.05 was consid-
ered statistically signiﬁcant.
3. Results
The baseline demographics and clinical characteristics of the
included patients are shown in Table 1. The majority of the pa-
tients were men (80%). 40% of cases were below the age of
45 years. Obesity was observed in 30% of patients. There
was history of smoking in 73.3% of patients. Hypertension
was detected in 30% of patients. Family history of MI or ische-
mic heart disease (IHD) was detected in 40% of patients.
Hypercholesterolemia was observed in 43.3% of patients.
Regarding risk factors, cases were classiﬁed into high risk
group with two or more risk factors and low risk group with
no or only one risk factor.
The classical risk factors, hypertension, obesity, smoking
and family history were signiﬁcantly higher in the MI patient
group than in the control. The value of HDL-cholesterol was
signiﬁcantly lower in patients than in controls, although serum
triglycerides, total cholesterol, LDL-cholesterol levels were
found to be signiﬁcantly higher in the patient group, (Table 2).
Table 1 Demographic and clinical data of patients.
Parameter Myocardial
infarction (n= 30)
Gender Male 24 (80%)
Female 6 (20%)
Age <45 years 12 (40%)
>45 years 18 (60%)
BMI (kg/m2) N (%) Mean ± SD 28.9 ± 3.1
Obese 9 (30%)
Non obese 21 (70%)
Smoking: N (%) Smoker 22 (73.3%)
Non smoker 8 (26.7%)
Blood pressure: N (%) Normal 21 (70%)
Hypertensive 9 (30%)
Family history of MI or IHD Absent 18 (60%)
Present 12 (40%)
Hypercholesterolemia No (%) 13 (43.3%)
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FV Leiden (G1691A) in the study population showed that
the GG genotype variant (the wild type) was the most preva-
lent one, Fig. 3 followed by GA (heterozygous), Fig. 4 and
then the (mutant homozygous) AA variant respectively,
Fig. 5. There was signiﬁcant increase in the heterozygous
FVL GA genotype among MI patients (26.7%) compared withMelting P
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Figure 3 Cases with wild type (homoz
Table 2 Comparison of clinical and biochemical data of the studie
Parameter Healthy control (n= 15)
Age (years) 43.2 + 4.3 years
BMI (kg/m2) 25.2 ± 2.5
Systolic blood pressure (mmHg) 122 ± 8
Diastolic blood pressure (mmHg) 78 ± 7
Total cholesterol (mg/dl) 156 ± 18
Triglycerides (mg/dl) 115 ± 20
HDL-C (mg/dl) 44 ± 2.1
LDL-C (mg/dl) 80 ± 13.5
Smoking N (%) 4 (26.6%)
Family history of MI 1 (6.6%)
P< 0.05 is statistically signiﬁcant, P> 0.05 is not statistically signiﬁcanthe control group (6.7%). The prevalence of homozygous AA
was signiﬁcantly increased in MI patients (3.3%) as compared
to the control group (0%). Additionally the allele frequency of
the mutated A allele in MI patients (16.7%) showed signiﬁcant
increase when compared with the control group (3.3%), as
shown on Tables 3 and 4.
As regards the MTHFR C677T gene polymorphism, The
percentage distribution of the different genotypes in the study
population showed that, the CC genotype variant (the wild
type), Fig. 6 was the most prevalent one followed by CT (het-
erozygous), Fig. 7 and then the (mutant homozygous) TT var-
iant respectively, Fig. 8. There was a signiﬁcant increase in the
heterozygous MTHFR:C677T CT genotype in MI patient
group (53.3%) compared with the control group (13.3%).
The prevalence of homozygous TT was signiﬁcantly increased
in MI patients (6.7%) as compared to the control group (0%).
Additionally the allele frequency of the mutated T allele in MI
patients (33.3%) showed signiﬁcant increase when compared
with the control group (6.7%), as shown in Tables 3 and 4.
Table 5 represents distribution of FVL genotypes among
low risk and high risk subjects and control group. Results
showed that low risk cases had a higher frequency of GA geno-
type as compared to high risk cases and control (28.6%, 25%,
and 6.7%) respectively. The prevalence of homozygous AA
was also signiﬁcantly increased in low risk cases (7.1%). None
of the high risk cases or control group had a genotype AA.
Table 6 represents distribution of MTHFR C677T geno-
types among low risk and high risk subjects and control
group. Results showed that low risk cases had a highereaks
rature (°C)
75706560
ygous Factor V) with GG genotype.
d groups.
Myocardial infarction (n= 30) P value
45.5 ± 4.8 years >0.05
28.9 ± 3.1 <0.05
145 ± 15 <0.05
88 ± 10 <0.05
195 ± 25 <0.05
155 ± 28 <0.05
39 ± 3.1 <0.05
105 ± 18.1 <0.05
22 (73.3%) <0.05
12 (40%) <0.05
t.
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Figure 5 Case with mutant (homozygous Factor V Leiden mutation) with AA genotype.
Table 3 Genotype frequencies in patients and controls.
Mutation/polymorphism Genotype Patients N= 30 Controls N= 15 P value
N% N%
Factor V:G1691A (FV Leiden) GG 21/30 (70%) 14/15 (93.3%) <0.05
GA 8/30 (26.7%) 1/15 (6.7%) <0.05
AA 1/30 (3.3%) 0/15 (0%) <0.05
MTHFR:C677T CC 12/30 (40%) 13/15 (86.7%) <0.05
CT 16/30 (53.3%) 2/15 (13.3%) <0.05
TT 2/30 (6.7%) 0/15 (0%) <0.05
P< 0.05 is statistically signiﬁcant.
Table 4 Allele frequency of the mutations/polymorphisms in patients and controls.
Mutation/polymorphism Allele Patients N= 60 Controls N= 30 P value
N% N%
Factor V:G1691A G 50/60 (83.3%) 29/30 (96.7%) <0.05
FV Leiden A 10/60 (16.7%) 1/30 (3.3%) <0.05
MTHFR:C677T C 40/60 (66.7%) 28/30 (93.3%) <0.05
T 20/60 (33.3%) 2/30 (6.7%) <0.05
P< 0.05 is statistically signiﬁcant.
118 H. Ezzat et al.frequency of heterozygous MTHFR:C677T CT genotype as
compared to high risk cases and control (64.3%, 43.75%,
and 13.3%) respectively. The prevalence of homozygous TTgenotype was signiﬁcantly increased in low risk cases
(14.3%). None of the high risk case or the control group
had genotype AA.
Melting Peaks
Temperature (°C)
56 07 57 08 5854 05 55 06
-(d
/dT
) F
luo
res
ce
nc
e (
64
0)
0.222
0.172
0.122
0.072
0.022
-0.028
Figure 6 Cases with wild type (homozygous MTHFR C677T) with CC genotype.
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Figure 7 Cases with heterozygous form of MTHFR (C677T) with CT genotype.
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Figure 8 Case with mutant (homozygous form of MTHFR C677T) with T/T genotype.
Table 5 Distribution of FVL genotypes among low risk and high risk subjects and control group.
Studied groups Factor V Leiden genotype
GG N (%) GA N (%) AA N (%)
Control group (n= 15) 14/15 (93.3%) 1/15 (6.7%) 0/15 (0%)
Total cases (n= 30) 21/30 (70%) 8/30 (26.7%) 1/30 (3.3%)
High risk cases (n= 16) 12/16 (75%) 4/16(25%) 0/16 (0%)
Low risk cases (n= 14) 9/14 (64.3%) 4/14 (28.6%) 1/14 (7.1%)
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Myocardial infarction may be a minor event in a lifelong
chronic disease, it may even go undetected, but it may also
be a major catastrophic event leading to sudden death [3].
Accurate diagnosis of MI has life-saving implications and re-
quires a careful assessment of both the patient’s history andthe ﬁndings on physical examination, 12-lead ECG, and car-
diac biomarker assays (cardiac-speciﬁc troponins T or I, or
muscle and brain fraction of creatine kinase (CK-MB) [19].
Genetic factors play a role in the development of coronary
artery disease. Among these genetic factors is the thrmbophilic
gene. The association between mutations/polymorphisms in
thrmbophilic gene and myocardial infarction as well as their
Table 6 Distribution of MTHFR:C677T genotypes among low risk and high risk subjects and control group.
Studied groups MTHFR:C677T genotype
CC N (%) CT N (%) TT N (%)
Control group (n= 15) 13/15 (86.7%) 2/15 (13.3%) 0/15 (0%)
Total cases (n= 30) 12/30 (40%) 16/30 (53.3%) 2/30 (6.7%)
High risk cases (n= 16) 9/16 (56.25%) 7/16 (43.75%) 0/16 (0%)
Low risk cases (n= 14) 3/14 (21.4%) 9/14 (64.3%) 2/14 (14.3%)
120 H. Ezzat et al.role as risk factors contributing to disease pathogenesis and
progression needs clariﬁcation.
In this study, classical risk factors, hypertension, obesity,
smoking and family history were signiﬁcantly high in the MI
patient group. The value of HDL-cholesterol was signiﬁcantly
lower in patients than in controls, although serum triglycer-
ides, total cholesterol, LDL-cholesterol, levels were found to
be signiﬁcantly higher in the patient group. These results were
in agreement with Segev et al. [10].
In our study BMI was higher among MI patients than con-
trol and obesity was observed in 30% of patients. This could
be explained by the fact that obesity is a risk factor for ische-
mic heart disease. Several studies reported that elevations of
both BMI and waist circumference are associated with in-
creased incidence of cardiovascular events [20,21].
In the present study we reported high prevalence of ciga-
rette smoking among patients groups (73.3%). These results
were in agreement with the results obtained by Heuschmann
et al. [22]. Rosendaal et al. demonstrated that interaction of
the FVL polymorphism with environmental factors such as
smoking increases the risk of MI [23].
In the present study we found that 30% of patients were
hypertensive. These results were in agreement with the results
obtained by Lewington et al. [24]. In addition, Turnbull re-
ported that lowering high BP is associated with a 30% to
40% reduction in risk of stroke [25].
In this work, two potential thrombophilic mutations/poly-
morphisms (FVL) and MTHFR C677T were investigated in
a group of patients with myocardial infarction and compared
to the control group.
In this study, the percentage distribution of the different
genotypes for FV Leiden (G1691A) in the study population
showed that the wild type GG genotype variant was the most
prevalent one, followed by heterozygous GA, and then the mu-
tant homozygous AA variant respectively. There was signiﬁ-
cant increase in the heterozygous FVL GA genotype among
MI patients (26.7%) compared with the control group
(6.7%). One MI patient only had the mutant homozygous
AA genotype (3.3%) as compared to the control group
(0%). Additionally the allele frequency of the mutated A allele
in MI patients (16.7%) showed signiﬁcant increase when com-
pared with the control group A allele frequency (3.3%).
Several studies have addressed the effect of factor V Leiden
on coronary artery disease. In a large study, among 224 pa-
tients with coronary artery disease, the factor V mutation
was found more often in the patients than in 196 controls
[26]. Rosendaal et al. demonstrate an association between
FV G1 691A polymorphisms and increased risk of MI in
young women [23].
Consistent with our results, the result reported by Mann-
ucci et al., on a large cohort of Italian patients who had MI,1880 patients with MI and an equal number of controls, they
demonstrated that the gain of function variant A allele of
FV Leiden (G1691A) was associated with an increased risk
of MI [27]. Satra et al. examined 523 patients using exercise-
rest myocardial perfusion single photon emission computed
tomography; they reported an association between FVL (het-
erozygous variant) and decrease myocardial perfusion, sug-
gesting that the process of coronary artery disease and also
patient prognosis may be adversely modiﬁed by FVL [28].
In a study by Emiroglu et al., among 220 patients, the prev-
alence of the heterozygous FVL mutation GA variants was
associated with higher prevalence of totally occluded coronary
arteries. Furthermore they demonstrated that the risk of left
ventricular aneurysm formation was signiﬁcantly higher in
FVL heterozygote group compared to wild type GG variants
[29].
As regards distributions of FVL genotypes among low risk
and high risk subjects and control group, results showed that
low risk cases had a higher frequency of GA genotype as com-
pared to high risk cases and control (28.6%, 25%, and 6.7%)
respectively. The prevalence of homozygous AA was signiﬁ-
cantly increased in low risk cases (7.1%). None of the high risk
cases or control group had genotype AA.
These results were in agreement with Van de Water and col-
leagues, who reported that the frequency of factor V Leiden
was signiﬁcantly increased (14.6%) in patients aged <50 years
in the study compared with 3.6% in the control group [30].
Also Settin et al. reported that, factor FV Leiden (G1691A)
mutation represents a signiﬁcant risk factor for AMI. They
concluded that frequency of FV Leiden (G1691A) mutation
was high among patients with AMI. So families of affected
subjects should be genotyped and counseled for proper pro-
phylaxis [31].
FV Leiden (G1691A) mutation (FVL) an arginine to gluta-
mine missense mutation in the Factor V (FV) gene at position
506 is the most prominent risk factor for venous thromboem-
bolism [32]. Factor V Leiden is found in approximately 5% of
Caucasians, and increases the risk of thrombosis ﬁve to eight-
fold for heterozygous carriers and 50–80-fold for homozygous
carriers [33]. Several mechanisms contribute to explanation of
prothrombotic tendency that is present in carriers of FVL
mutation. The amino acid substitution in FV resulting in a fail-
ure of APC to recognize a major cleavage site on factor V, lead
to increased thrombin generation [11]. In case of FV Leiden
mutation APC is not able to bind the mutant FV region
around the most favored cleavage site at Arg 506 and conse-
quently APC cannot regulate the activity of FVL via the pro-
teolysis independent mechanism [34].
On the other side, several studies did not report any associ-
ation between FVL mutation and coronary artery disease. The
atherosclerosis, thrombosis, and vascular biology Italian study
Prevalence of thrombophilic gene polymorphisms (FVL G1691A and MTHFR C677T) 121group, investigated the association between FV Leiden
(G1691A) mutation/polymorphisms and myocardial infarc-
tion, in a large sample of young patients with myocardial
infarction chosen because, their disease is more likely to be re-
lated to a genetic predisposition to a prothrombotic state.
They reported that FVL G1691A were not associated with
an increased risk of myocardial infarction [35].
In cohort of Indian patients consisting of 51 patients aged
below 50 years presenting with acute coronary syndromes,
Himabindu et al. reported that factor V Leiden mutation is
not a predisposing factor for acute coronary syndromes [36].
Also Yamada et al., found that FV G1691A was not associ-
ated with an increased risk of AMI [37].
As regards MTHFR C677T gene polymorphism, the per-
centage distribution of the different genotypes in the study
population showed that the wild type CC genotype was the
most prevalent one followed by heterozygous CT, and then
the mutant homozygous TT variant respectively. There was a
signiﬁcant increase in the heterozygous MTHFR C677T CT
genotype among MI patients (53.3%) compared with the con-
trol group (13.3%). The prevalence of homozygous MTHFR
TT genotype was signiﬁcantly increased in MI patients
(6.7%) as compared to the control group (0%). Additionally
the allele frequency of the mutated T allele in MI patients
(33.3%) showed a signiﬁcant increase when compared with
the control group T allele frequency (6.7%).
Our results are consistent with previous studies that showed
a signiﬁcant increase in the frequency of the MTHFR C677T
polymorphism among patients with CAD. Den Heijer et al. re-
ported that the population frequencies of homozygous
MTHFR C677T vary by ethnic group and the heterozygous
MTHFR C677T mutation is more common than the homozy-
gous variant [16].
Kluijtmans et al. reported that both the homozygous TT
mutant variant and heterozygous CT genotype result in ele-
vated homocysteine concentration concluded that the homozy-
gous TT genotype is a modest but signiﬁcant risk factor for
CAD [38]. The ﬁnding in our study is consistent with a previ-
ous report by Gu¨lec et al., in which MTHFR C677T transition
was found to be a risk factor for premature MI [39].
Almawi et al. in a sample from the Bahrain population stud-
ied a total of 96 patients with CADand 404 healthy subjects and
in the study done by Ghazouni et al. on 352 Tunisian patients
withCAD, and 390matched healthy subjects they demonstrated
that signiﬁcantly higher frequency of T allele and homozygous
TT genotype was seen in patients vs. control subjects, and they
concluded that MTHFR C677T mutation is associated with
CAD and with elevated homocysteine levels [40,41].
In contrast to our results, Hsu et al. reported that the
C677T mutation of the MTHFR gene is not associated with
the risk of coronary artery disease or venous thrombosis
among Chinese in Taiwan [42]. Yilmaz et al. and Caner
et al. did not ﬁnd any association between MTHFR C677T
polymorphism and increased risk for CAD in Turkish patients
[43,44].
As regards the distributions of MTHFR C677T genotypes
among low risk and high risk subjects and control group.
Our results showed that the low risk cases had a higher fre-
quency of heterozygous MTHFR CT genotype as compared
to high risk cases and control (64.3%, 43.75%, and 13.3%)
respectively. The prevalence of homozygous TT genotype
was signiﬁcantly increased in low risk cases (14.3%). Noneof the high risk cases neither the control group had genotype
AA.
The present study is in agreement with a previous study by
Alam et al. who demonstrated positive association of MTHFR
C677T gene polymorphism and CAD and they recommended
further study with larger sample size including assessment of
vitamin status to better clarify the relationship between
MTHFR genotypes and CAD [45]. Hendy et al. also reported
that there is a strong relationship between MTHFR C677T
gene polymorphism and hypertension, hypercholesterolemia
and hyperhomocysteinemia [46].
MTHFR plays a central role in the metabolism of the ami-
no acid homocysteine. Deﬁciency of MTHFR may be associ-
ated with an increase in plasma homocysteine, which in turn
is associated with an increased risk of vascular disease [47].
A common polymorphism that may contribute to hyperhomo-
cysteinemia has been reported in the MTHFR gene. The
C677T (Ala-to-Val) transition, which produces thermolability
and somewhat reduced enzyme activity in vitro, was ﬁrst de-
scribed by Kang et al. [48].
Hyperhomocysteinemia has been identiﬁed as a risk factor
for atherosclerosis. Experimental evidence suggests that homo-
cysteine facilitates the vascular oxidative process, thereby
altering the coagulation system, and reduces the vasomotor
regulation of the endothelium [49]. Outinen et al. reported that
Hyperhomocysteinemia may contribute to both atherosclerotic
and thrombotic processes by modulating vascular cell prolifer-
ation and promoting prothrombotic activity in the vascular
wall [50].
The contradictory results for V Leiden (G 1691 A) and
MTHFR (C677T) between different studies could be attrib-
uted to relatively small sample size, and ethnic heterogeneity.5. Conclusion
This study observed that factor V Leiden (FVL G1691 A) and
methylene tetrahydrofolate reductase (MTHFR C677T) gene
polymorphisms are probably risk factors for MI among Egyp-
tian cases particularly if integrated with other environmental
and genetic risk factors. We recommended screening high risk
patients for this polymorphism and the use of speciﬁc throm-
boprophylaxis to prevent recurrent thrombotic disease. Fur-
ther studies in a large sample size are needed to conﬁrm
these results.
Conﬂicts of interest
All authors declare no conﬂict of interest. There is no ﬁnancial
and personal relationship with other people or organizations
that could inappropriately inﬂuence this work.References
[1] Wang YC, Hwang JJ, Hung CS, Kao HL, Chiang FT, Tseng CD.
Outcome of primary percutaneous coronary intervention in
octogenarians with acute myocardial infarction. J Formos Med
Assoc 2006;105:451–8.
[2] Liu PY, Chen JH, Li YH, Wu HL, Shi GY. Synergistic effect of
stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A
polymorphism with smoking on the onset of young acute
myocardial infarction. Thromb Haemost 2003;90:132–9.
122 H. Ezzat et al.[3] Thygesen K, Alpert JS, White HD. Universal deﬁnition of
myocardial infarction. Eur Heart J 2007;28(20):2525–38.
[4] Egred M, Viswanathan G, Davis GK. Myocardial infarction in
young adults. Postgrad Med J 2005;81(962):741–5.
[5] Cambien F, Poirier O, Mallet C, Tiret L. Coronary heart disease
and genetics in epidemiologist’s view. Mol Med Today
1997;3:197–203.
[6] Linneman NB, Schindewolf M, Zgoura D. Are patients with
thrombophilia and previous venous thromboembolism at higher
risk for arterial thrombosis? Thromb Res 2008;121(6):743–50.
[7] Eifert S, Rasch A, Beiras-Fernandez A, Nollert G, Reichart B,
Lohse P. Gene polymorphisms in APOE, NOS3, and LIPC genes
may be risk factors for cardiac adverse events after primary
CABG. J Cardiothorac Surg 2009;19(4):46.
[8] Incalcaterra E, Hoffmann E, Averna M, Caimi G. Genetic risk
factors in myocardial infarction at young age. Minerva Cardio-
angiol 2004;52(4):287–312.
[9] Musino L, Rossi R, Partenza A, Mureddu G, Zinellu A, Pilo P,
et al. Hemostatic gene polymorphisms in young sardinian with
non-fatal acute myocardial infarction. Front Biosci (Elite Ed)
2010;1(2):559–65.
[10] Segev A, Ellis MH, Segev F, Friedman Z, Reshef T, Sparkes JD,
et al. High prevalence of thrombophilia among young patients
with myocardial infarction and few conventional risk factors. Int J
Cardiol 2005;98(3):421–4.
[11] Voetsch B, Loscalzo J. Genetic determinants of arterial throm-
bosis. Arterioscler Thromb Vasc Biol 2004;24:216–29.
[12] Jadaon MM. Epidemiology of activated protein C resistance and
factor V Leiden mutation in the mediterranean region. Mediterr J
Hematol Infect Dis 2011;3(1):e2011037.
[13] Andreassi MG, Botto N, Cocci F, Battaglia D, Antonioli E, et al.
Methylene tetrahydrofolate reductase gene C677T polymorphism,
homocysteine, vitamin B12 and DNA damage in coronary artery
disease. Hum Genet 2003;112(2):171–7.
[14] Hanson N, Aras O, Yang F, Tsai M. C677T and A1 298C
polymorphisms of the methylene tetrahydrofolate reductase gene:
incidence and effect of combined genotypes on plasma fasting and
post-methionine load homocysteine in vascular disease. Clin
Chem 2001;47:661–6.
[15] Trimmer EE. Methylene tetrahydrofolate reductase: biochemical
characterization and medical signiﬁcance. Curr Pharm Des
2013;19(14):2574–93.
[16] Den Heijer M, Lewington S, Clarke A. Homocysteine, MTHFR
and risk of venous thrombosis: a meta-analysis of published
epidemiological studies. J Thromb Haemost 2005;3(2):292–9.
[17] Graham I, Atar D, Borch-Johnsen K, et al. European guidelines
on cardiovascular disease prevention in clinical practice: executive
summary: Fourth Joint Task Force of the European Society of
Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (Constituted by representatives of
nine societies and by invited experts). Eur Heart J
2007;28(19):2375–414.
[18] Steptoe A, Kivima¨ki M. Stress and cardiovascular disease. Nat
Rev Cardiol 2012;9(6):360–70.
[19] Kumar A, Cannon CP. Acute coronary syndromes diagnosis and
management, part I. Mayo Clin Proc 2009;84(10):917–38.
[20] Corral AR, Somers VK, Sierra-Johnson J, Jensen MD, Thomas
RJ, et al. Diagnostic performance of body mass index to detect
obesity in patients with coronary artery disease. Eur Heart J
2007;28:2087–93.
[21] See R, Abdullah SM, McGuire DK, Khera A, Patel MJ, et al.
The association of differing measures of overweight and obesity
with prevalent atherosclerosis: the Dallas Heart Study. J Am Coll
Cardiol 2007;50:752–9.
[22] Heuschmann PU, Heidrich J, Wellmann J, Kraywinkel K, Keil U.
Stroke mortality and morbidity attributable to passive smoking in
Germany. Eur J Cardiovasc Prev Rehabil 2007;14(6):793–5.[23] Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V
Leiden (resistance to activated protein C) increases the risk of
myocardial infarction in young women. Blood 1997;89:2817–21.
[24] Lewington S, Clarke R, Qizilbash N, et al. Age-speciﬁc relevance
of usual blood pressure to vascular mortality: a meta-analysis of
individual data for one million adults in 61 prospective studies.
Lancet 2002;360:1903–13.
[25] Turnbull F. Effects of different blood-pressure lowering regimens
on major cardiovascular events: results of prospectively-designed
overviews of randomised trials. Lancet 2003;362:1527–35.
[26] Ma¨rz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt
I. Mutation in coagulation factor V associated with resistance to
activated protein C in patients with coronary artery disease.
Lancet 1995;345:526.
[27] Mannucci PM, Asselta R, Duga S, Guella I, et al. The association
of factor V leiden with myocardial infarction is replicated in 1880
patients with premature disease. J Thromb Haemost
2010;8(10):2116–21.
[28] Satra M, Samara M, Wozniak G, Tzavara C, Kontos A, et al.
Sequence variations in the FII, FV, F13A1, FGB and PAI-1 genes
are associated with differences in myocardial perfusion. Phar-
macogenomics 2011;12(2):195–203.
[29] Emiroglu O, Durdu S, Egin Y, Akar A, et al. Thrombotic gene
polymorphisms and postoperative outcome after coronary artery
bypass graft surgery. J Cardio-Thorac Surg 2011;6:120.
[30] Van De Water N, French J, Lund M, Hyde T, White H, Browett
P. Prevalence of factor V Leiden and prothrombin variant G
20210 A in patients age <50 years with no signiﬁcant stenoses at
angiography three to four weeks after myocardial infarction. J
Am Coll Cardiol 2000;36(3):717–22.
[31] Settin A, Dowaidar M, El-Baz R, Abd-Alsamad A, El-Sayed I,
Naser M. Frequency of factor V Leiden mutation in Egyptian
cases with myocardial infarction. Hematology 2008;13(3):170–4.
[32] Couturaud F, Kearon C, Leroyer C, Mercier B, et al. Incidence of
venous thromboembolism in ﬁrst degree relatives of patients with
venous thromboembolism who have factor V Leiden. Thromb
Haemost 2006;96:744–9.
[33] Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and
thrombophilia: background and mechanisms. Thromb Haemost
2007;98(3):530–42.
[34] Nicolaes GA, Bock PE, Segers K, Wildhagen KC, Dahlback B,
Rosing J. Inhibition of thrombin formation by active site mutated
(S360A) activated protein. J Biol Chem 2010;285(30):22890–900.
[35] Atherosclerosis, Thrombosis, and Vascular Biology Italian Study
Group: no evidence of association between prothrombotic gene
polymorphisms and the development of acute myocardial infarc-
tion at a young age. Circulation 2003; 107: 1117–1122.
[36] Himabindu G, Rajasekhar D, Latheef K, Sarma PV, Vana-
jakshamma V, et al. Factor V Leiden mutation is not a
predisposing factor for acute coronary syndromes. Indian Heart
J 2012;64(6):570–5.
[37] Yamada Y, Ichihara S, Nishida T. Molecular genetics of
myocardial infarction. Genomic Med 2008;2:7–22.
[38] Kluijtmans L, Kastelein J, Lindemans J. Thermolabile methylene
tetrahydro-folate reductase in coronary artery disease. Circulation
1997;96:2573–7.
[39] Gu¨lec S, Aras O, Akar E, Tutar E, Omu¨rlu¨ K, Avci F, et al.
Methylene tetrahydrofolate reductase gene polymorphism and
risk of premature myocardial infarction. Clin Cardiol
2001;24:281–4.
[40] Al Mawi WY, Ameen G, Tamim H, Finan RR, et al. Factor V
G1691A, prothrombin G20210A, and methylenetetrahydrofolate
reductase [MTHFR] C677T gene polymorphism in angiograph-
ically documented coronary artery disease. J Thromb Thrombol-
ysis 2004;17(3):199–205.
[41] Ghazouani L, Abboud N, Mtiraoui N, et al. Homocysteine and
methylene tetrahydrofolate reductase C677T and A1298C poly-
Prevalence of thrombophilic gene polymorphisms (FVL G1691A and MTHFR C677T) 123morphisms in Tunisian patients with severe coronary artery
disease. J Thromb Thrombolysis 2009;27:191–7.
[42] Hsu LA, Ko YL, Wang SM, Chang CJ, Hsu TS, Chiang CW,
et al. The C677T mutation of the methylene tetrahydrofolate
reductase gene is not associated with the risk of coronary artery
disease or venous thrombosis among Chinese in Taiwan. Hum
Hered 2001;51:41–5.
[43] Yilmaz H, Isbir S, Agachan B, Ergen AB, Isbir T. C677T
Mutation of methylene tetrahydrofolate reductase gene and serum
homocysteine levels in Turkish patients with coronary artery
disease. Cell Biochem Funct 2006;24(1):87–90.
[44] Caner M, Bircan R, Sevinc D, Benli F, Guney AI, Kurtoglu N.
MTHFR, prothrombin and factor V gene variants in Turkish
patients with coronary artery stenosis. Genetics Mol Biol
2008;31(4):836–8.
[45] Alam MA, Husain SA, Narang R, et al. Association of poly-
morphism in the thermolabile 5, 10 methylene-tetrahydrofolate
reductase gene and hyperhomocysteinemia with coronary artery
disease. Mol Cell Biochem 2008;310:111–7.[46] Hendy OM, Abd Al Moneam E, Allam M, et al. Frequency of
thrombotic gene mutations in diabetic patients with and without
coronary artery disease. Med J Cairo Univ 2011;79(2):197–204.
[47] Fo¨dinger M, Ho¨rl WH, Sunder-Plassmann G. Molecular biology
of 5, 10-methylene tetrahydrofolate reductase. J Nephrol
2000;13(1):20–33.
[48] Kang SS, Wong P, Susmano A, Sora J, Norusis M, Ruggie N.
Thermolabile methylene tetrahydrofolate reductase: an inherited
risk factor for coronary artery disease. Am J Hum Genet
1991;48:536–45.
[49] Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N,
et al. Hyperhomocysteinemia enhances vascular inﬂammation
and accelerate atherosclerosis in a murine model. J Clin Invest
2001;107(6):675–83.
[50] Outinen P, Sood S, Liaw P, Sarge K, Maeda N, Hirsh J.
Characterization of the stress-inducing effects of homocysteine.
Biochem J 1998;332(1):213–21.
